相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Low Molecular Weight Cyclin E Overexpression Shortens Mitosis, Leading to Chromosome Missegregation and Centrosome Amplification
Rozita Bagheri-Yarmand et al.
CANCER RESEARCH (2010)
Targeting the Cyclin E-Cdk-2 Complex Represses Lung Cancer Growth by Triggering Anaphase Catastrophe
Fabrizio Galimberti et al.
CLINICAL CANCER RESEARCH (2010)
Cyclin-dependent kinase inhibitors: a survey of recent patent literature
Herve Galons et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2010)
Altered Subcellular Localization of Tumor-Specific Cyclin E Isoforms Affects Cyclin-Dependent Kinase 2 Complex Formation and Proteasomal Regulation
Nikki A. Delk et al.
CANCER RESEARCH (2009)
Low molecular weight cyclin E is specific in breast cancer and is associated with mechanisms of tumor progression
Hannah Wingate et al.
CELL CYCLE (2009)
Pharmacodynamic Effects of Seliciclib, an Orally Administered Cell Cycle Modulator, in Undifferentiated Nasopharyngeal Cancer
Wen-Son Hsieh et al.
CLINICAL CANCER RESEARCH (2009)
Seliciclib in malignancies
Ibrahim T. Aldoss et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2009)
A mechanism linking extra centrosomes to chromosomal instability
Neil J. Ganem et al.
NATURE (2009)
Autophagy: A novel mechanism of synergistic cytotoxicity between doxorubicin and roscovitine in a sarcoma model
Laura A. Lambert et al.
CANCER RESEARCH (2008)
Meriolins (3-(pyrimidin-4-yl)-7-azaindoles): Synthesis, kinase inhibitory activity, cellular effects, and structure of a CDK2/cyclin A/meriolin complex
Aude Echalier et al.
JOURNAL OF MEDICINAL CHEMISTRY (2008)
CDK inhibitors in cancer therapy: what is next?
Marcos Malumbres et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2008)
Meriolins, a new class of cell death-inducing kinase inhibitors with enhanced selectivity for cyclin-dependent kinases
Karima Bettayeb et al.
CANCER RESEARCH (2007)
Overexpression of the low molecular weight cyclin E in transgenic mice induces metastatic mammary carcinomas through the disruption of the ARF-p53 pathway
Said Akli et al.
CANCER RESEARCH (2007)
A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days
C. Benson et al.
BRITISH JOURNAL OF CANCER (2007)
Cyclin-dependent kinase pathways as targets for cancer treatment
GI Shapiro
JOURNAL OF CLINICAL ONCOLOGY (2006)
Tumor-specific low molecular weight forms of cyclin E induce genomic instability and resistance to p2l, p27, and antiestrogens in breast cancer
S Akli et al.
CANCER RESEARCH (2004)
Roscovitine and other purines as kinase inhihitors. From starfish oocytes to clinical trials
L Meijer et al.
ACCOUNTS OF CHEMICAL RESEARCH (2003)
Aloisines, a new family of CDK/GSK-3 inhibitors. SAR study, crystal structure in complex with CDK2, enzyme selectivity, and cellular effects
Y Mettey et al.
JOURNAL OF MEDICINAL CHEMISTRY (2003)
Cyclin E and survival in patients with breast cancer.
K Keyomarsi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Tumor-specific proteolytic processing of cyclin E generates hyperactive lower-molecular-weight forms
DC Porter et al.
MOLECULAR AND CELLULAR BIOLOGY (2001)
Suppression of spontaneous chromosomal rearrangements by S phase checkpoint functions in Saccharomyces cerevisiae
KJ Myung et al.
CELL (2001)
Novel splice variants of cyclin E with altered substrate specificity
Donald C. Porter et al.
NUCLEIC ACIDS RESEARCH (2000)
分享论文
